Compare VC & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VC | DYN |
|---|---|---|
| Founded | 2000 | 1984 |
| Country | United States | United States |
| Employees | 10000 | 258 |
| Industry | Auto Parts:O.E.M. | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.1B |
| IPO Year | 2000 | 2020 |
| Metric | VC | DYN |
|---|---|---|
| Price | $112.40 | $17.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 14 |
| Target Price | ★ $125.50 | $37.00 |
| AVG Volume (30 Days) | 654.4K | ★ 1.6M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $3,768,000,000.00 | N/A |
| Revenue This Year | $2.39 | N/A |
| Revenue Next Year | $5.21 | N/A |
| P/E Ratio | $100.06 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $81.21 | $8.25 |
| 52 Week High | $128.32 | $25.00 |
| Indicator | VC | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 65.51 | 45.24 |
| Support Level | $106.64 | $16.47 |
| Resistance Level | $117.66 | $19.65 |
| Average True Range (ATR) | 4.47 | 0.97 |
| MACD | 0.41 | -0.15 |
| Stochastic Oscillator | 74.14 | 18.41 |
Visteon Corp is an automotive supplier. It manufactures electronics products for original equipment vehicle manufacturers including Ford, Nissan, Renault, Mazda, BMW, General Motors, and Honda, etc. The company offers information displays, instrument clusters, head-up displays, infotainment systems, telematics solutions, and Smartcore. The Company's reportable segment is Electronics. The Electronics segment provides vehicle cockpit electronics products to customers, including digital instrument clusters, domain controllers with integrated driver assistance systems, displays, Android-based infotainment systems, and battery management systems. Geographically, it operates in North America, Europe, China, Asia-Pacific, and South America and Others.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.